Background
cancer, CHASIT, Urothelial cancer, MIBC, UC
CANCER, DISEASE
Urothelial cancer (UC) is the 10th most common cancer worldwide [Pre-operative immunotherapy for MIBC is currently investigated in several clinical trials, either as monotherapy or concurrent with chemotherapy [In patients with locally advanced irresectable or node-positive UC, treatment with ipilimumab and nivolumab resulted in a pCR of 46% at interim analysis [The CHASIT study aims to improve the pCR rate and clinical outcome in patients with locally advanced irresectable or node-positive UC of the bladder, upper urinary tract or urethra. Patients with at least stable disease after treatment with platinum-based induction chemotherapy will receive 3 cycles of avelumab, an anti-PD-L1 antibody, followed by radical surgery. We hypothesize that sequential chemo-immunotherapy is more effective in obtaining pCR compared to induction chemotherapy alone, which results in improved clinical outcome.